enicepatide vs VK2735

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

enicepatide

Developed by Roche and partners

Phase 3 in Obesitypeptide
Reliable signal

NCT06525935 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled Phase 2 trial in 469 adults with obesity and at least one weight-related condition. Enicepatide 24 mg produced significantly greater weight loss than placebo at week 48, 22.5% placebo-adjusted by one analysis method and 18.3% by another, both p<0.001, meeting the trial primary comparison.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: November 2027 · NCT07589686 (registry estimate)

Reported efficacy

Percent Change in Body Weight from Baseline to Week 48: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) (met)

Result source: NCT06525935

VK2735

Developed by Viking Therapeutics

Phase 3 in Obesitypeptide
Reliable signal

NCT06828055 · Phase 2 · completed

This randomized, triple-blind, placebo-controlled Phase 2 trial (n=280) in adults with obesity found that oral VK2735 produced significantly greater weight loss than placebo at 13 weeks, up to 12.2% versus 1.3% (placebo-adjusted 10.9%, p<0.0001).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT07838740 (registry estimate)

Reported efficacy

Percent (relative) change from baseline in body weight after 13 weeks of treatment: Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001 (met)

Result source: NCT06828055

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointenicepatideVK2735
Body weight, % change—Trial running · NCT07670416—Trial running · NCT07104500
Weight loss of 5% or more—Trial running · NCT07670416—Trial running · NCT07104500
Weight loss of 10% or more—Trial running · NCT07670416—Trial running · NCT07104500
Waist circumference, change (cm)—Trial running · NCT07670416—Trial running · NCT07104500

Body weight, % change

enicepatide
—Trial running · NCT07670416
VK2735
—Trial running · NCT07104500

Weight loss of 5% or more

enicepatide
—Trial running · NCT07670416
VK2735
—Trial running · NCT07104500

Weight loss of 10% or more

enicepatide
—Trial running · NCT07670416
VK2735
—Trial running · NCT07104500

Waist circumference, change (cm)

enicepatide
—Trial running · NCT07670416
VK2735
—Trial running · NCT07104500
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

enicepatide
Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) NCT06525935 · Phase 2 · design grade: strong · publication or press release
VK2735
Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001 NCT06828055 · Phase 2 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: enicepatide's landscape · VK2735's landscape